Reducing residual thrombotic risk in patients with peripheral artery disease: impact of the COMPASS trial

José Luis Hernández MD, PhD, Francisco S Lozano MD, PhD, Vincent Riambau MD, PhD, Manuel Almendro-Delia MD, PhD, Juan Cosín-Sales MD, PhD, Sergi Bellmunt-Montoya MD, PhD, Javier Garcia-Alegria MD, PhD, Xavier Garcia-Moll MD, FESC, FACC, Juan José Gomez-Doblas MD, PhD, José R Gonzalez-Juanatey MD, PhD, Carmen Suarez Fernández MD

Article Type

Review

Published

In this narrative review, data about how to reduce residual risk through the best antithrombotic
approach among patients with peripheral artery disease, with a particular focus
on the COMPASS trial, are updated in order to provide some
practical recommendations about its use in this population.

Read more

Register for alerts

I would like to be contacted by Drugs in Context when new articles are posted.